Predict your next investment

Corporation
HEALTHCARE
lepumedical.com

See what CB Insights has to offer

Investments

7

Portfolio Exits

1

Service Providers

3

About Lepu Medical

Lepu Medical (SHE:300003) is specialized in developing, manufacturing and marketing the high-tech medical devices and equipment.

Lepu Medical Headquarter Location

37 Chaoqian Road, Changping District

Beijing, Beijing, 102200,

China

+86 10 80120666

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Lepu Medical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lepu Medical Rank

Latest Lepu Medical News

Kehua, Lepu, Other Chinese Covid-19 Test Kit Makers Warn of Profit Squeeze Amid Tighter Oversight

Jul 18, 2022

(Yicai Global) July 18 -- Shanghai Kehua Bio-Engineering, Lepu Medical Technology and other Chinese Covid-19 detection kit manufacturers are forecasting an up-to-90-percent plunge in profit in the first half from the same period last year as the Chinese government calls for prices to come down more and steps up the monitoring of quality controls. Kehua Bio-Engineering’s first-half profit could crash as much as 90 percent from the year before to CNY35 million (USD5.1 million), the medical device maker said on July 14. Net profit at Lepu Medical may sink between 20 percent and 30 percent over the period to between CNY1.2 billion (USD180 million) and CNY1.3 billion, the Beijing-based company said the same day. Of this, income from its Covid-19 testing businesses could dive 80 percent. In May, the Chinese government asked testing agencies to further cut the price of nucleic acid tests to no more than CNY16 (USD2.40) each, less than half what they cost at the beginning of the year. And last month, the country’s cabinet ordered a nationwide probe into testing agencies following the frequent reporting of inaccurate test results. Some 238 labs have been told to smarten up their acts and 15 have had their licenses revoked so far. “Tighter oversight and stricter quality control requirements have pushed up the operating costs of novel coronavirus testing laboratories while revenue is shrinking,” said Lu Hongzhou, president of the Third People’s Hospital of Shenzhen. “This will cause some smaller labs to withdraw from the industry.” Even though the market share of EasyDiagnosis Biomedicine’s test kits is increasing, pricing was lower in the second quarter than in the first quarter, the Wuhan-based medical reagent maker said on July 15. To make up for the lack of manpower and testing labs, automated facilities, such as nucleic acid sampling robots, mobile testing vehicles, detection gas membranes and makeshift labs, will be on the rise. “It is urgent to improve the automation of lab testing as the higher detection efficiency and fewer man-made errors means it has a promising future," Lu said. Editor: Kim Taylor

Lepu Medical Investments

7 Investments

Lepu Medical has made 7 investments. Their latest investment was in Beijing Ruijian as part of their Series A on April 4, 2022.

CBI Logo

Lepu Medical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/7/2022

Series A

Beijing Ruijian

Yes

1

4/6/2022

Series A - II

Subscribe to see more

Subscribe to see more

10

8/23/2021

Series B

Subscribe to see more

Subscribe to see more

10

7/1/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/28/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/7/2022

4/6/2022

8/23/2021

7/1/2019

11/28/2018

Round

Series A

Series A - II

Series B

Series A

Series C

Company

Beijing Ruijian

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Lepu Medical Portfolio Exits

1 Portfolio Exit

Lepu Medical has 1 portfolio exit. Their latest portfolio exit was Lepu Biotechnology on February 23, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/23/2022

IPO

$99M

Public

1

Date

2/23/2022

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

1

Lepu Medical Service Providers

7 Service Providers

Lepu Medical has 7 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

IPO

Valuation Firm

Valuation

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

IPO

Subscribe to see more

Subscribe to see more

Provider Type

Valuation Firm

Subscribe to see more

Subscribe to see more

Service Type

Valuation

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

You May Also Like

Q
Quasar

Quasar specializes in the manufacturing of products for the medical device market, and focuses on minimally invasive devices and disposables.

S
SMT

SMT develops and manufactures cardiac products in India. Its product portfolio includes coronary stents (drug-eluting and bare-metal), renal stents, angioplasty balloon catheters, and other cardiac accessories in India and abroad.

Translumina Logo
Translumina

Translumina is a global Interventional cardiovascular devices company. Translumina is a fully integrated product development and manufacturing company with manufacturing facilities in Germany and India. The company commercializes products in over 50 countries globally through 2 distinct business entities, International and India.

BridgePoint Medical Logo
BridgePoint Medical

BridgePoint Medical is focused on developing technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.In September 2012, BridgePoint medical was acquired by Boston Scientific. The valuation of BridgePoint Medical was undisclosed. Other terms of the deal were not released.

S
Shanghai Kinetic

Shanghai Kinetic (300326.SZ) is a medical device manufacturer for multidisciplinary specialties including Orthopedics, Cardiovascular and Sports Medicine.

Silk Road Medical Logo
Silk Road Medical

Silk Road Medical develops and manufactures less-invasive medical devices intended to improve the treatment of carotid artery disease through proprietary transcarotid therapies. By focusing on proven surgical principles and developing technology for vascular specialists, the company can improve the lives of people with carotid artery disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.